-
RPM International Beats Q1 Earnings Estimates
2024 Oct 02, 2:06pm | 646RPM International (NYSE: RPM) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.64 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings...
-
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
2024 Oct 02, 1:53pm | 791Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare neurological disorder. The Fast Track designation from the FDA facilitates rapid...
-
Why NetApp's AI-Driven Data Solutions Make It a Top Tech Stock
2024 Oct 02, 12:39pm | 877NetApp Inc. (NASDAQ: NTAP) is an intelligent data infrastructure company that offers data-centric software and networking hardware that enable enterprises to manage and use their data. The computer and technology sector leader provides on-premise and hybrid cloud solutions with...
-
Citi Analysts Turn More Bullish on Walmart Stock: Time to Buy?
2024 Oct 01, 2:32pm | 577Walmart (NYSE: WMT), the consumer defensive giant, has been on an impressive run in 2024, surging over 51% year-to-date (YTD) and outperforming both its sector and the broader market. Recently, analysts at Citi upgraded their stance on the stock, becoming even more bullish after already being long-...
-
McCormick Q3 Earnings Top Estimates, MKC Volumes Improve Y/Y
2024 Oct 01, 2:11pm | 1118McCormick & Company, Incorporated (NYSE: MKC) reported solid third-quarter fiscal 2024 results, wherein the top and bottom lines beat the Zacks Consensus Estimate, and earnings increased year over year. The company achieved a significant milestone by delivering overall global positive volume...
-
TJX Stock: A Buying Opportunity Before the Holiday Rush
2024 Oct 01, 1:35pm | 977The off-price trend has taken the retail wholesale sector by storm in the current economic climate. Consumers are trying to stretch their dollars but don't want to sacrifice quality. This rules out low-quality and low-price outlets like Dollar Tree Inc. (NASDAQ: DLTR) or even Dollar General Co...
-
Rubrik: Riding the AI Wave in the Cybersecurity Boom
2024 Oct 01, 12:46pm | 1092Rubrik Inc. (NYSE: RBRK) is a leading cybersecurity company specializing in data protection and recovery, and it is quickly becoming a key player in the rapidly expanding cybersecurity sector. Since its initial public offering (IPO) in April, Rubrik has demonstrated strong financial performance,...
-
Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
2024 Oct 01, 11:40am | 920Micron Technology, Inc. proved the doubters and analysts wrong with a Babe Ruth-style homerun earnings report that saw revenues nearly double YoY driven by the artificial intelligence (AI) boom. The irony is that at least three analysts downgraded, trimmed estimates or lowered price targets...
-
Carnival Posts Strong Q3 Earnings, Analysts Suspect 'Some Conservatism Built Into Q4 Guidance'
2024 Oct 01, 10:30am | 655Shares of Carnival Corp (NYSE:CCL) tanked in early trading on Tuesday, even after the company reported upbeat third-quarter earnings. The Miami-based company reported its results amid an exciting earnings season. Here are some key analyst takeaways. Truist Securities analyst Patrick Scholes...
-
HOLX Stock Gains From New Offerings Despite Macro Issues
2024 Sep 27, 3:29pm | 1199Hologic (NASDAQ: HOLX) has been gaining from new strategic product launches across Diagnostics and Breast Health. However, macroeconomic issues and unfavorable FX headwinds continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently. Major Factors Driving HOLX Stock Growth Among...
-
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
2024 Sep 27, 3:03pm | 615Sage Therapeutics, Inc. (NASDAQ: SAGE) announced that partner Biogen (NASDAQ: BIIB) has terminated its rights related to the investigational neurology candidate, SAGE-324. A phase II study on SAGE-324 for treating essential tremor failed to meet the primary endpoint in July. The termination will be...
-
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
2024 Sep 27, 2:45pm | 783Axonics, Inc. (NASDAQ: AXNX) has received regulatory approval from the Therapeutic Goods Administration to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge device features a 20-year functional life and reduces recharge frequency to once every...
-
Here's Why Surgery Partners Could Be the Next Hot Takeover
2024 Sep 27, 12:47pm | 767With the stock markets trading near highs again and the start of a lower interest rates cycle, the backdrop for mergers, spin-offs, and acquisitions continues to improve. Elevated stock prices are just as good as currency when trying to acquire another company. The Sept. 24, 2024, announcement that...
-
Accenture Is A 'Key Beneficiary Of' GenAI: Analysts Raise Forecasts After Q4 Results
2024 Sep 27, 10:36am | 584Accenture Plc (NYSE:ACN) shares came under pressure in early trading on Friday, even after the company reported upbeat results for its fiscal fourth quarter. The company reported its results amid an exciting earnings season. Here are some key analyst takeaways. Piper Sandler On Accenture Analyst...
-
Reinsurance Group Rallies 35.1% YTD: What's Driving the Stock?
2024 Sep 27, 10:33am | 1041Reinsurance Group of America (NYSE: RGA) shares have rallied 35.1% year to date (YTD) compared with the industry's growth of 21.5%. The Finance sector and the Zacks S&P 500 index have returned 14.3% and 20% YTD, respectively. With a market capitalization of $14.39 billion, the average...
Coverage of Earnings Beats.